Record-Breaking Survival in HER2 Metastatic Breast Cancer
Final results of the CLEOPATRA trial show that dual HER2 blockade with the combination of pertuzumab and trastuzumab plus chemotherapy extended overall survival (OS) by almost 16 months compared with trastuzuÂmab plus chemotherapy in patients with HER2-positive metastatic breast cancer. This should become the new standard of care for metastatic [ Read More ]